This pilot study will examine the safety of the cannabinoid cannabidiol (Epidiolex) in a
human laboratory model of clinically relevant withdrawal. The study will be a residential
within-subject comparison; all participants will receive placebo dosing and active
cannabidiol. Results may be used to support an R01 grant application to more closely examine
this hypothesis.